To the full analysis
Oscar Health stock: growth
OSCROscar Health reported $11.7B in revenue for fiscal 2025, up 27.5% on the prior year, up 90.8% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
66.3%
per year from 2019 to 2025, per share 15.4%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2019 | |
|---|---|---|
| Revenue | 81.8% | 66.3% |
| Revenue per share | 78.5% | 15.4% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | 38.4% | no data |
| Free cash flow per share | 35.8% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2019 | $553.78M | −$261.18M | −$191.37M |
| 2020 | $589.64M | −$406.83M | $208.71M |
| 2021 | $1.92B | −$572.61M | −$207.63M |
| 2022 | $4.13B | −$606.28M | $351.34M |
| 2023 | $5.86B | −$270.73M | −$297.74M |
| 2024 | $9.18B | $25.43M | $950.3M |
| 2025 | $11.7B | −$443.15M | $1.06B |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 10 Nov 2026, previously Neutral
- Valuation signal Fairly valued since 12 Nov 2026, previously Undervalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.